Retatrutide (development code LY3437943) is an investigational once-weekly injectable weight loss medication developed by Eli Lilly and Company the same pharmaceutical company behind Mounjaro (tirzepatide) and the oral GLP-1 pill orforglipron (Foundayo)
The formulary is just the first step
In short, BPC-157 is a promising research compound for accelerating the bodys natural healing processes
Not necessarily, because the side effects come from the drug rather than how you take it
Iron, ferritin, hereditary ferritinopathy, and neurodegeneration
Im a certified personal trainer and nutrition coach who has spent years helping women lose weight through strength training, sustainable nutrition habits, and, sometimes, macros